BIOMARKER RESULTS FROM PENELOPE, A RANDOMISED PHASE III TRIAL EVALUATING CHEMOTHERAPY plus /- PERTUZUMAB FOR PLATINUM-RESISTANT OVARIAN CANCER (PROC) WITH LOW TUMOUR HER3 MRNA EXPRESSION

被引：0

作者：

Colombo, N. ^{[1
,2
]}

Gonzalez-Martin, A. ^{[3
,4
]}

Oestergaard, M. Z. ^{[5
]}

Rau, J. ^{[6
]}

Canzler, U. ^{[7
,8
]}

Fabbro, M. ^{[9
,10
]}

Martinez, J. ^{[11
,12
]}

Kiermaier, A. ^{[5
]}

Mitchell, L. ^{[13
]}

Kurzeder, C. ^{[14
,15
]}

机构：

[1] Univ Milano Bicocca, Div Med Gynecol Oncol, MaNGO, Milan, Italy

[2] Univ Milano Bicocca, European Inst Oncol, Milan, Italy

[3] GEICO, Dept Med Oncol, Madrid, Spain

[4] MD Anderson Canc Ctr Spain, Madrid, Spain

[5] F Hoffmann La Roche, Oncol Biomarker Dev, Basel, Switzerland

[6] Univ Marburg, Coordinating Ctr Clin Trials, Marburg, Germany

[7] AGO, Dept Gynecol & Obstet, Dresden, Germany

[8] Univ Hosp Carl Gustav Carus, Dresden, Germany

[9] GINECO, Dept Med Oncol, Montpellier, France

[10] Ctr Lutte Canc Val dAurelle, Montpellier, France

[11] GEICO, Dept Med Oncol, El Palmar, Spain

[12] Hosp Virgen Arrixaca, El Palmar, Spain

[13] F Hoffmann La Roche, Global Med Affairs Biometr, Basel, Switzerland

[14] AGO, Dept Med Oncol, Essen, Germany

[15] Kliniken Essen Mitte, Essen, Germany

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2015年 / 25卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ESGO-1093

引用

页码：415 / 417

页数：3

共 43 条

[41] Primary results from ENGOT-Ov41/GEICO 69-O/ANITA, a double-blind placebo-controlled phase 3 trial evaluating atezolizumab combined with platinum-based chemotherapy and maintenance niraparib for recurrent ovarian cancer with a platinum-free interval >6 months
Gonzalez-Martin, Antonio
Rubio-Perez, Maria Jesus
Heitz, Florian
Christensen, Rene Depont
Colombo, Nicoletta
Gorp, Toon Van
Oaknin, Ana
Leary, Alexandra
Gaba, Lydia
Lebreton, Coriolan
Miguel De Sande Gonzalez, Luis
Romeo, Margarita
Redondo, Andres
Barretina-Ginesta, Maria-Pilar
Perez-Fidalgo, Alejandro
Santaballa, Ana
Bermejo, Maria Jose
Bruchim, Ilan
Ray-Coquard, Isabelle
Selle, Frederic
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A35 - A36
[42] First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) plus /- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)
Miles, D.
Cameron, D.
Bondarenko, I.
Lyudmila, M.
Alcedo, J. C.
Lopez, R. I.
Im, S. A.
Canon, J. L.
Shparyk, Y.
Yardley, D.
Masuda, N.
Ro, J.
Hubeaux, S.
Quah, C.
Bais, C.
O'Shaughnessy, J.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S287 - S288
[43] Ipatasertib (IPAT) plus paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial
Turner, N.
Dent, R.
O'Shaughnessy, J.
Kim, S-B.
Isakoff, S.
Barrios, C. H.
Saji, S.
Bondarenko, I.
Nowecki, Z.
Lian, Q.
Reilly, S-J.
Hinton, H.
Wongchenko, M.
Mani, A.
Oliveira, M.
ANNALS OF ONCOLOGY, 2020, 31 : S354 - S355

← 1 2 3 4 5 →